Replies to post #4644 on Biotech Values

[rkrw]

Randy, not to be a wet blanket, I'm sure there are many more cases, but one real life example is itmn/actimmune for ipf. An australian investigator showed stunning phase II results that weren't replicated in itmn's pivotal trial. Your comments are just about the same as mine were about itmn prior to the actual outcome. Turned out in the phase II there likely was biased patient selection going on and further it couldn't be confirmed that all the australian patients indeed had ipf, in fact a few didn't.

I do hope like heck the phase II data are very good and confirm what was seen in Mexico.

[rstor1]

+++ Dew has mentioned the financing. Again a good point. Why not wait until all PK testing done. Are they making a stronger hand when dealing with partners, are they worried of marginal data in PK testing having an impact on raising cash, ever see a bio with enough money, are they hiding safety concerns that will impact their ability to raise cash, etc.... +++

Too much meaning can be attached to the financing.

We just went through a 6-month or so period when financing was not readily available. I am now seeing substantial fianincing activity in baby bios again. Perhaps it's just the slice of the market that I follow.

I think that the rule of thumb for bio CEO's is that you grab the cash when it's available, because you never know when it will dry up. And it's apparently available again.

Regards,
Bob